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Objective: To determine the serum levels and frequency of antiphospholipid antibodies (aPLs) 
and confirm the clinical importance of this antibodies in patients with autoimmune blistering 
disease (ABD). 
Methods: IgG and IgM anti-cardiolipin antibodies (aCL), IgG anti-cardiolipin-β2 glycoprotein 
I complex antibody (aCL/β2GPI), and IgG anti-phosphatidylserine-prothrombin complex 
antibody (aPS/PT) were examined with an enzyme-linked immunosorbent assay in 71 patients 
with ABD, including pemphigus vulgaris, pemphigus foliaceous, and bullous pemphigoid.  
Results: The prevalence of IgG aCL, IgM aCL, aCL/β2GPI, and IgG aPS/PT were positive for 
22.4%, 9.1%, 9.9%, and 25.4% of the ABD patients, respectively, while they were not detected 
in any of the normal controls. Ten of 20 (50%) patients with ABD who were attending our 
hospital in 2004 were positive for aPLs, and thromboembolism was detected in 7/10 (70%) 
patients with aPLs.  
Conclusion: aPLs are frequently detected in ABD patients. Careful examination and follow up 




aPL: antiphospholipid antibody 
Ab: antibody 
ABD: autoimmune blistering disease 
aCL: anti-cardiolipin antibody 
aCL/β2GPI: anti-cardiolipin-β2 glycoprotein I complex antibody 
aPS/PT: anti-phosphatidylserine-prothrombin complex antibody 
PV: pemphigus vulgaris 
PF: pemphigus foliaceous 
BP: bullous pemphigoid 




Autoimmune blistering disease (ABD) is a typical acquired organ-specific autoimmune 
disease forming blisters on the skin and/or mucous membranes 1. Pemphigus, including 
pemphigus vulgaris (PV) and pemphigus foliaceous (PF), is an autoimmune intraepidermal 
blistering diseases that target desmoglein 2. Bullous pemphigoid (BP) is an autoimmune 
subepidermal blistering disease that target BP180/NC16a 3. 
The antiphospholipid syndrome (APS) is an acquired multisystem disorder 
characterized by hypercoagulation in which thrombosis and recurrent fetal loss develop 4. The 
serological markers for this syndrome are antiphospholipid antibodies (aPLs), such as the 
lupus anticoagulant (LA), anti-cardiolipin antibody (aCL) 5, 6, antibody against anticardiolipin 
β2-glycoprotein I complex antibody (CL/β2GPI), and anti-phosphatidylserine-prothrombin 
complex antibody (aPS/PT) 7, 8.  
aPLs are frequently found in patients with systemic autoimmune diseases, especially in 
systemic lupus erythematosus (SLE). They are also found in patients with organ-specific 
autoimmune diseases 9-16, however the frequency of aPL in ABD remains unknown. In this 
study, we investigated whether aPLs were detected in patients with ABD, and whether these 




Patients and serum samples 
 Serum samples were obtained from 22 patients with PV (6 males and 16 females; age, 
55 ± 12 (mean  ± SD) years), 21 patients with PF (12 males and 9 females; age, 62 ± 12 years), 
and 28 patients with BP (12 males and 16 females; age 69 ± 15 years). The patients were 
diagnosed according to their clinical, pathological, and immunological features typical for 
each ABD 17. None of the ABD patients were treated with systemic corticosteroids or 
immunosuppressive agents when the serum samples were collected. Age-matched 32 healthy 
Japanese people (12 males and 20 females; age, 60 ± 15 years), and 29 patients with SLE (3 
males and 26 females; age, 37 ± 14 years), who fulfilled the criteria of the American College of 
Rheumatology 18 were used as controls. 
 
Detection of aPLs  
 The aCL of the IgG and IgM isotypes, and IgG aPS/PT were measured with specific 
ELISAs (Medical & Biological Laboratories, Nagoya, Japan), and the IgG aCL /β2GPI was 
also measured with specific ELISAs (Yamasa, Tokyo, Japan), according to the manufacturer’s 
protocol. LA was determined according to the guidelines recommended by the Subcommittee 
on Lupus Anticoagulant/Phospholipid Dependent Antibodies 19. 
 
Clinical assessment 
 Eighteen of the 71 ABD patients examined for aPLs and 2 with other autoimmune 
subepidermal blistering diseases (one cicatrial pemphigoid and one linear IgA bullous 
dermatosis) attended our hospital in 2004. Eighteen of the 20 ABD patients were treated with 
systemic corticosteroids or immunosuppressive agents when the serum and plasma samples 
were collected. Only one patient (61-year-old male patient with PV) has symptomatic of 
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thromboembolism (skin ulcers of the legs and mononeuropathy multiplex). We examined aPLs 
and clinical signs of APS with magnetic resonance imaging scans of the brain, 
ventilation/perfusion pulmonary scintigraphy, electrocardiography, echocardiography, and 
phlebography, and we enquired as to the history of the intrauterine fetal loss.  
 The protocol was approved by the Kanazawa University Graduate School of Medical 
Science, and informed consent was obtained from all patients. 
 
Statistical analysis  
 Statistical analysis was performed using Fisher's exact probability test for the 




Prevalence of aPLs in patients with ABD, SLE, and normal controls 
 Values higher than the mean + 2SD of the normal control serum samples were 
considered positive in this study. IgG aCL was detected more frequently in the patients with 
ABD (22.4%), PV (23.8%), PF (25.0%), BP (19.2%), and SLE (31.0%) than in the normal 
controls (0%, p<0.01, respectively, Figure 1A). The detection rate of IgM aCL was higher in 
the patients with PV (15.0%, p<0.05) and SLE (20.7%, p<0.01) than in normal controls (0%, 
Figure 1B). IgG aCL/β2GPI was detected more frequently in the patients with BP (14.3%, 
p<0.05) and SLE (27.6%, p<0.01) than in the normal controls (0%, Figure 1C). IgG aPS/PT 
was detected significantly higher in the patients with ABD (25.4%, p<0.01), PV (18.2%, 
p<0.05), PF (23.8%, p<0.05), BP (32.1%, p<0.01), and SLE (55.2%, p<0.01) than in the 
normal controls (0%, Figure 1D).  
 
Association of aPL with clinical features 
 LA, IgG aCL, IgM aCL, aCL/β2GPI, and aPS/PT were detected in 6/20 (30%), 7/20 
(35%), 3/14 (21%), 0/20 (0%), and 3/17 (18%) patients with ABD attending our hospital in 
2004, respectively (Table I). Ten of 20 (50%) patients with ABD were positive for any one of 
aPLs, and five of ten patients had plural aPLs. Thromboembolism was detected in 7/10 (70%) 
patients with aPLs, while a history of intrauterine fetal loss was not found in any of the patients. 




 In the present study, IgG aCL, IgM aCL, IgG aCL/β2GPI, and IgG aPS/PT were 
positive for 22.4%, 9.1%, 9.9%, and 25.4% of ABD patients, respectively (Figure 1). 
Thromboembolism was detected in high frequency (7/10 cases, 70%) in ABD patients with 
aPLs (Table I). 
 It is well known that aPLs are frequently detected in SLE and some systemic 
autoimmune diseases, and SLE comprised 36% of the cases among those with secondary APS 
20. However, recent studies indicate that aPLs have also been detected in organ-specific 
autoimmune diseases, such as insulin dependent diabetes mellitus (34%) 9, 10, myasthenia gravis 
(22%) 11, autoimmune thyroid diseases (43~55%) 12, 13, inflammatory bowel disease (16~18%) 
14, 15, and localized scleroderma (46%) 16. Nevertheless, aPL positive patients with these 
diseases infrequently show clinical signs of thromboembolism 9, 11-16. Only in patients with 
insulin dependent diabetes mellitus, the presence of aPLs is associated with complications 
throughout the pregnancy 10. Our findings suggest that ABD is another organ-specific 
autoimmune disease that can be accompanied by APS. 
 Since most of thromboembolism was asymptomatic in ABD patients (Table I), 
hypercoagulative states due to aPLs may be modest in ABD patients compared with patients 
with primary APS or SLE. Nonetheless, we propose that patients with ABD should be 
examined for the presence of aPLs, since the frequency of some aPLs was significantly higher 
than that in normal controls. While systemic corticosteroid is often used for treatment of ABD, 
this may enhance the hypercoagulative states. Therefore, careful observation and follow up 
may be required to prevent symptomatic thrombotic events in patients with aPLs. Further 
follow-up studies, especially with a large patient group, will be needed to clarify the clinical 
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Table I.  The profiles of antiphospholipid antibodies in patients with autoimmune 
blistering disease, and clinical involvements of thrombosis 
Diag Age Sex Thrombosis LA IgG aCL IgM aCL aCL/β2GPI aPS/PT
37 M Femoral head + - - - - 
46 M N.D. - - - - - 
61 M Skin ulcer, Nerve, Brain + 11.7 N.D. - 18.6 
63 F Lung, Brain + 27.7 17.8 - - 
64 F Popliteal vein + 10.8 - - - 
PV 
71 M Brain - 32.2 11.5 - 33.4 
47 F N.D. - - - - - 
48 F - - - 27.8 - - 
54 M N.D. - - - - - 
56 M N.D. - - - - - 
60 M Lung + 27.5 - - 26.9 
67 M N.D. - - - - - 
70 M N.D. - - - - - 
PF 
73 M N.D. - - N.D. - N.D.
30 M Brain + - - - - 
62 F - - 21.4 - - - 
73 F N.D. - - N.D. - - 
BP 
85 F N.D. - - N.D. - - 
CP 80 F N.D. - - N.D. - N.D.
LAD 61 F - - 17.9 N.D. - N.D.
 
N.D.: not done 
CP: cicatrial pemphigoid 
LAD: linear IgA bullous dermatosis 
Femoral head: avascular necrosis of the femoral head 
Nerve: mononeuropathy multiplex 
Brain: cerebral thrombosis 
Lung: pulmonary embolism 




Figure 1. (A) IgG Abs against cardiolipin (CL), (B) IgM Abs against CL, (C) IgG Abs 
against CL/β2GPI, and (D) IgG Abs against PS/PT in serum samples from patients with 
autoimmune blistering disease (ABD), pemphigus vulgaris (PV), pemphigus foliaceous 
(PF), bullous pemphigoid (BP), systemic lupus erythematosus (SLE), and normal 
controls (CTL). Each Ab levels were determined with specific ELISA. A broken line 
represents the cut-off value. Percentage above the broken line indicates the frequency of 
antibody-positive patients in each subgroup. 
 
 




